LISTED natural medicines and health products company Bod Australia has settled on the R&D trial process for its sublingual wafer delivery form of medicinal cannabis and will commence manufacture of the stock in coming weeks ahead of Phase I Clinical trials.
The trial will test the safety, tolerability and pharmacokinetics of Bod's proprietary ECs315 extract in a sublingual wafer formulated by specialty pharmaceutical firm and exclusive partner, iX Biopharma.
Bod also expects to shortly receive the first shipment of ECs315 CBD in MCT oil from its Swiss partner Linnea, which is being imported following permission from the Office of Drug Control and will be distributed via the TGA's Special Access Scheme Category B.
The company promised to implement consistent education and support initiatives for all parties involved in the prescription and dispensing of CBD oils, including a professional education program for relevant specialists & pharmacies.
Australian Pharmaceutical Industries has a comprehensive Bod distribution deal (PD 06 Apr).
The above article was sent to subscribers in Pharmacy Daily's issue from 14 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 May 18
